Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Home
ETF
SLDB
SLDB
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
SLDB News
FDA CBER Head Dr. Vinay Prasad to Depart, Impact on Moderna and Rare Disease Stocks
1d ago
Benzinga
Relmada Therapeutics Shares Surge 40.8% on Promising Trial Data
1d ago
Benzinga
Marvell Technology Surges After Strong Q4 Earnings Report
4d ago
Benzinga
Solid Biosciences Secures $240 Million Private Placement
4d ago
seekingalpha
Solid Biosciences Secures $240 Million Private Placement Financing
4d ago
Newsfilter
Solid Biosciences Receives Positive FDA Feedback
Feb 09 2026
NASDAQ.COM
Solid Biosciences Aligns with FDA on Late-Stage Trial for DMD Treatment
Feb 09 2026
seekingalpha
Solid Biosciences Aligns with FDA to Advance SGT-003 for Duchenne
Feb 09 2026
Newsfilter
Solid Biosciences CEO to Present at Biotech Summit 2026
Feb 06 2026
Newsfilter
Sarepta Shares Rise as 3-Year Elevidys Study Results Offer Promise.
Jan 26 2026
Barron's
Solid Biosciences (SLDB) Completes Enrollment for SGT-003 Clinical Trial
Jan 14 2026
seekingalpha
Solid Biosciences (SLDB) Receives FDA Orphan Drug Designation for SGT-212, Phase 1b Trial Initiated
Jan 13 2026
NASDAQ.COM
Solid Biosciences Receives FDA Fast Track and Orphan Drug Designations for SGT-212, Initiates Phase 1b Trial
Jan 12 2026
Globenewswire
Solid Biosciences Grants 7,000 RSUs to New Employee as Inducement
Jan 05 2026
Globenewswire
Biotech Sector Sustains After-Hours Trading Gains
Dec 18 2025
NASDAQ.COM
Solid Biosciences Advances Duchenne Screening with RUSP Inclusion
Dec 16 2025
Globenewswire
Show More News
